AAPG · Ascentage Pharma Group International
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-05-21 | Zhai Yifan |
Chief Medical Officer |
Convert↑
Filing footnotes — Ordinary Shares (Indirect)
Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Ordinary Shares
(I)
|
95,575 |
| 2026-05-21 | Yang Dajun |
Director, Chairman and CEO |
Convert↑
|
Ordinary Shares
|
95,575 |
| 2026-05-21 | Yang Dajun |
Director, Chairman and CEO |
Convert↓
Filing footnotes — Restricted stock units (Direct)
Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. |
Restricted stock units
|
95,575 |
| 2026-05-21 | Zhai Yifan |
Chief Medical Officer |
Convert↓
Filing footnotes — Restricted stock units (Indirect)
Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026. |
Restricted stock units
(I)
|
95,575 |
| 2026-05-21 | Zhai Yifan |
Chief Medical Officer |
Convert↓
Filing footnotes — Restricted stock units (Direct)
Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person on 05/20/2026. |
Restricted stock units
|
92,746 |
| 2026-05-21 | Yang Dajun |
Director, Chairman and CEO |
Convert↑
Filing footnotes — Ordinary Shares (Indirect)
Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
Ordinary Shares
(I)
|
92,746 |
| 2026-05-21 | Zhai Yifan |
Chief Medical Officer |
Convert↑
|
Ordinary Shares
|
92,746 |
| 2026-05-21 | Yang Dajun |
Director, Chairman and CEO |
Convert↓
Filing footnotes — Restricted stock units (Indirect)
Represents the vesting in full on 5/21/2026 of the RSUs granted to the Reporting Person's spouse on 05/20/2026. |
Restricted stock units
(I)
|
92,746 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Restricted stock units (Direct)
The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. |
Restricted stock units
|
298,195 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Restricted stock units (Indirect)
The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. |
Restricted stock units
(I)
|
103,365 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted stock units (Direct)
Each restricted stock unit (the "RSUs") represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and have no expiration date. |
Restricted stock units
|
103,365 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Options (Indirect)
The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. |
Options
(I)
|
103,364 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Restricted stock units (Direct)
Each restricted stock unit (the "RSUs") represent a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vested on 05/21/2026 and had no expiration date. |
Restricted stock units
|
95,575 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Options (Indirect)
The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. |
Options
(I)
|
298,194 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted stock units (Direct)
The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. |
Restricted stock units
|
214,999 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted stock units (Indirect)
The RSUs vested on 05/21/2026 and had no expiration date. |
Restricted stock units
(I)
|
95,575 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Options (Direct)
The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on November 26, 2026, 2027, 2028 and 2029 and expire ten years from the date of grant. |
Options
|
103,364 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted stock units (Direct)
The RSUs vested on 05/21/2026 and had no expiration date. |
Restricted stock units
|
92,746 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Options (Indirect)
The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. |
Options
(I)
|
214,988 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Options (Direct)
The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. |
Options
|
298,194 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Restricted stock units (Indirect)
The RSUs vested on 05/21/2026 and had no expiration date. |
Restricted stock units
(I)
|
92,746 |
| 2026-05-20 | Yang Dajun |
Director, Chairman and CEO |
Award↑
Filing footnotes — Restricted stock units (Indirect)
The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. |
Restricted stock units
(I)
|
214,999 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Options (Direct)
The exercise price of the options is in HKD and the exercise price included in the table represents conversion to USD based on the exchange rate as of the date of grant. The options vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and expire ten years from the date of grant. |
Options
|
214,988 |
| 2026-05-20 | Zhai Yifan |
Chief Medical Officer |
Award↑
Filing footnotes — Restricted stock units (Indirect)
The RSUs vest in four equal increments on May 21, 2027, 2028, 2029 and 2030 and have no expiration date. |
Restricted stock units
(I)
|
298,195 |
| 2026-04-20 | Misra Veet |
Chief Financial Officer |
Award↑
Filing footnotes — Restricted stock units (Direct)
Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest immediately and have no expiration date. |
Restricted stock units
|
18,584 |